Key result
Novel benzamide-derived Kv1.3 inhibitors show potent preclinical activity with an IC50 reaching ~122 nmol/L.
Why the study?
The voltage-gated potassium channel Kv1.3 is a key regulator of T-cell activation and a validated target for autoimmune and inflammatory diseases, motivating the expansion of a library of benzamide-derived inhibitors.
Novel benzamide-derived carbamate derivatives demonstrate potent submicromolar inhibition of the Kv1.3 channel, supporting their potential development for immunomodulatory applications.
Supports further preclinical testing of these Kv1.3 inhibitors; leaves open immunomodulatory applications pending in vivo validation.
The voltage-gated potassium channel Kv1.3 is a key regulator of T-cell activation and a validated therapeutic target for autoimmune and inflammatory diseases. In this study, a ligand-based design strategy was employed to expand a library of benzamide-derived K v 1.3 inhibitors. Starting from a previously optimised thiophene-based inhibitor, structu ral modifications were introduced to the 2-methoxybenzamide moiety and the central tetrahydropyran or cyclohexane scaffold. A series of ketone, hydroxy, and carbamate derivatives was synthesised and evaluated for K v 1.3 inhibition using whole-cell patch-clamp electrophysiology. Structure-activity relationship analysis revealed that cis -isomers in the hydroxy series exhibited stronger activity than their trans counterparts, with some analogues displaying submicro-molar IC 50 values. In the carbamate series, trans -isomers were generally more potent, with trans - 18 and trans - 16 achieving IC 50 values of 122 and 166 nmol L–1, respectively. These results provide valuable insights into the design of K v 1.3 inhibitors and support further development of these compounds for immunomodulatory applications.
No takes yet. Share an insight, caveat, or question.
Nasburg et al. (2025) studied Autoimmune and inflammatory diseases. Benzamide-derived Kv1.3 inhibitors was evaluated on Kv1.3 inhibition (IC50). Novel benzamide-derived Kv1.3 inhibitors demonstrated potent activity, with trans-isomers in the carbamate series achieving IC50 values of 122 and 166 nmol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: